These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36201473)

  • 1. Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program.
    Beier L; Lu S; França LR; Marler S; Lip GYH; Huisman MV; Teutsch C; Halperin JL; Zint K; Diener HC; Baker L; Ma CS; Paquette M; Bartels DB; Dubner SJ; Lyrer P; Senges J; Rothman KJ
    PLoS One; 2022; 17(10):e0274237. PubMed ID: 36201473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
    Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
    J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry : Trends in antithrombotic therapy use in China.
    Liu X; Feng G; Marler SV; Huisman MV; Lip GYH; Ma C
    Thromb J; 2023 Aug; 21(1):83. PubMed ID: 37528405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.
    Huisman MV; Teutsch C; Lu S; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Lohmann R; Gurusamy VK; Bartels DB; Lip GYH;
    Clin Res Cardiol; 2022 May; 111(5):548-559. PubMed ID: 35294623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry.
    Mazurek M; Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Lu S; Lip GYH;
    Thromb Haemost; 2017 Dec; 117(12):2376-2388. PubMed ID: 29212125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic Usage, Including Three-Year Outcomes With Dabigatran and Vitamin K Antagonists for Atrial Fibrillation, in Eastern Europe: A Descriptive Analysis From Phase 3 of the GLORIA-AF Registry.
    Bergler-Klein J; Gotcheva N; Kalējs O; Kalarus Z; Kovačić D; Peršić V; Shlyakhto E; Uuetoa T; Huisman MV; Lip GYH; Vinereanu D;
    Am J Ther; 2024 Jan-Feb 01; 31(1):e1-e12. PubMed ID: 38231576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
    Huisman MV; Lip GY; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Teutsch C; Zint K; Ackermann D; Clemens A; Bartels DB
    Am Heart J; 2014 Mar; 167(3):329-34. PubMed ID: 24576516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme.
    Mazurek M; Halperin JL; Huisman MV; Diener HC; Dubner SJ; Ma CS; Rothman KJ; Healey JS; Teutsch C; Paquette M; França LR; Lu S; Bartels DB; Lip GYH
    Europace; 2020 Jan; 22(1):47-57. PubMed ID: 31651951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program.
    McIntyre WF; Conen D; Olshansky B; Halperin JL; Hayek E; Huisman MV; Lip GYH; Lu S; Healey JS
    Clin Cardiol; 2018 Jun; 41(6):744-751. PubMed ID: 29546729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulant selection in relation to the SAMe-TT
    Ntaios G; Huisman MV; Diener HC; Halperin JL; Teutsch C; Marler S; Gurusamy VK; Thompson M; Lip GYH; Olshansky B;
    Hellenic J Cardiol; 2021; 62(2):152-157. PubMed ID: 33338644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Lu S; Bartels DB; Lip GYH;
    Am Heart J; 2018 Apr; 198():55-63. PubMed ID: 29653649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.
    Bayer V; Kotalczyk A; Kea B; Teutsch C; Larsen P; Button D; Huisman MV; Lip GYH; Olshansky B
    J Am Heart Assoc; 2022 Mar; 11(6):e023907. PubMed ID: 35243870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
    Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
    Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF).
    Kim H; Lee YS; Kim TH; Cha MJ; Lee JM; Park J; Park JK; Kang KW; Shim J; Uhm JS; Park HW; Choi EK; Kim JB; Kim C; Kim J; Joung B
    Korean J Intern Med; 2020 Jan; 35(1):99-108. PubMed ID: 31014064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program.
    López-Sendón JL; Alonso-Rodríguez D; Barón-Esquivias G; Cosin-Sales J; Marín F; Galera-Llorca J; Jiménez N; Marler S; Huisman MV; Lip GYH;
    Med Clin (Barc); 2022 Aug; 159(4):177-182. PubMed ID: 34895750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
    Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
    BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.